The effect of spironolactone in patients with resistant
arterial hypertension in relation to baseline blood pressure
and secondary causes of hypertension

J 2013

The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension

VACLAVIK, Jan, Richard SEDLAK, Jiří JARKOVSKÝ, Eva KOCIANOVA, Milos TABORSKY et. al.

Basic information

Original name

The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension

Authors

VACLAVIK, Jan (203 Czech Republic), Richard SEDLAK (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, guarantor, belonging to the institution), Eva KOCIANOVA (203 Czech Republic) and Milos TABORSKY (203 Czech Republic)

Edition

Biomedical Papers, Olomouc: Palacky University, Olomouc, Palacky University, 2013, 1213-8118

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.661

RIV identification code

RIV/00216224:14110/13:00072692

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.5507/bp.2012.078

UT WoS

000316989100009

Keywords in English

resistant hypertension; spironolactone; clinical trials; blood pressure; secondary hypertension

Abstract

V originále

Aims. There are currently limited data about whether the effect of spironolactone in patients with resistant arterial hypertension depends on baseline blood pressure and the presence of a secondary cause of hypertension. Methods. Patients with office systolic blood pressure (BP) > 140 mmHg or diastolic BP > 90 mmHg, despite treatment with at least 3 antihypertensive drugs including a diuretic, were randomly assigned to receive spironolactone or a placebo for 8 weeks in a double-blind, placebo-controlled, multicentre trial (ASPIRANT). Results. Analyses were done with 55 patients treated with spironolactone. The degree of BP reduction after 8 weeks of spironolactone treatment did not differ significantly between the three tertiles of baseline systolic BP and patients with and without a secondary cause of hypertension. The reduction of office systolic, office diastolic BP and office pulse pressure was significantly lower in the highest tertile with baseline diastolic BP > 97 mmHg. Conclusions. Spironolactone treatment is effective to a similar extent both in patients with and without a secondary cause of hypertension and regardless of the baseline value of systolic BP. Less effect of spironolactone was found in patients with the highest baseline diastolic BP.

Citovat

VACLAVIK, Jan, Richard SEDLAK, Jiří JARKOVSKÝ, Eva KOCIANOVA and Milos TABORSKY. The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension. Biomedical Papers, Olomouc: Palacky University. Olomouc: Palacky University, 2013, vol. 157, No 1, p. 50-55. ISSN 1213-8118. Available from: https://dx.doi.org/10.5507/bp.2012.078.

@article{1170060,
   author = {Vaclavik, Jan and Sedlak, Richard and Jarkovský, Jiří and Kocianova, Eva and Taborsky, Milos},
   article_location = {Olomouc},
   article_number = {1},
   doi = {http://dx.doi.org/10.5507/bp.2012.078},
   keywords = {resistant hypertension; spironolactone; clinical trials; blood pressure; secondary hypertension},
   language = {eng},
   issn = {1213-8118},
   journal = {Biomedical Papers, Olomouc: Palacky University},
   title = {The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension},
   volume = {157},
   year = {2013}
}

TY  - JOUR
ID  - 1170060
AU  - Vaclavik, Jan - Sedlak, Richard - Jarkovský, Jiří - Kocianova, Eva - Taborsky, Milos
PY  - 2013
TI  - The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension
JF  - Biomedical Papers, Olomouc: Palacky University
VL  - 157
IS  - 1
SP  - 50-55
EP  - 50-55
PB  - Palacky University
SN  - 12138118
KW  - resistant hypertension
KW  - spironolactone
KW  - clinical trials
KW  - blood pressure
KW  - secondary hypertension
N2  - Aims. There are currently limited data about whether the effect of spironolactone in patients with resistant arterial hypertension depends on baseline blood pressure and the presence of a secondary cause of hypertension. Methods. Patients with office systolic blood pressure (BP) > 140 mmHg or diastolic BP > 90 mmHg, despite treatment with at least 3 antihypertensive drugs including a diuretic, were randomly assigned to receive spironolactone or a placebo for 8 weeks in a double-blind, placebo-controlled, multicentre trial (ASPIRANT). Results. Analyses were done with 55 patients treated with spironolactone. The degree of BP reduction after 8 weeks of spironolactone treatment did not differ significantly between the three tertiles of baseline systolic BP and patients with and without a secondary cause of hypertension. The reduction of office systolic, office diastolic BP and office pulse pressure was significantly lower in the highest tertile with baseline diastolic BP > 97 mmHg. Conclusions. Spironolactone treatment is effective to a similar extent both in patients with and without a secondary cause of hypertension and regardless of the baseline value of systolic BP. Less effect of spironolactone was found in patients with the highest baseline diastolic BP.
ER  -

VACLAVIK, Jan, Richard SEDLAK, Jiří JARKOVSKÝ, Eva KOCIANOVA and Milos TABORSKY. The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension. \textit{Biomedical Papers, Olomouc: Palacky University}. Olomouc: Palacky University, 2013, vol.~157, No~1, p.~50-55. ISSN~1213-8118. Available from: https://dx.doi.org/10.5507/bp.2012.078.

Detailed Information on Publication Record